IGC Pharma, Inc. (IGC)

IGC Pharma Statistics

Total Valuation

IGC Pharma has a market cap or net worth of $28.74 million. The enterprise value is $27.17 million.

Market Cap	28.74M
Enterprise Value	27.17M

Important Dates

The next estimated earnings date is Friday, November 15, 2024, before market open.

Earnings Date	Nov 15, 2024
Ex-Dividend Date	n/a

Share Statistics

IGC Pharma has 75.64 million shares outstanding. The number of shares has increased by 20.46% in one year.

Current Share Class	75.64M
Shares Outstanding	75.64M
Shares Change (YoY)	+20.46%
Shares Change (QoQ)	+13.34%
Owned by Insiders (%)	9.79%
Owned by Institutions (%)	21.83%
Float	68.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.75
Forward PS	38.10
PB Ratio	3.64
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	25.58
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.04.

Current Ratio	1.77
Quick Ratio	0.76
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -126.20% and return on invested capital (ROIC) is -57.43%.

Return on Equity (ROE)	-126.20%
Return on Assets (ROA)	-47.82%
Return on Capital (ROIC)	-57.43%
Revenue Per Employee	$15,851
Profits Per Employee	-$198,552
Employee Count	67
Asset Turnover	0.08
Inventory Turnover	0.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +21.80% in the last 52 weeks. The beta is 1.29, so IGC Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.29
52-Week Price Change	+21.80%
50-Day Moving Average	0.37
200-Day Moving Average	0.41
Relative Strength Index (RSI)	47.43
Average Volume (20 Days)	239,612

Short Selling Information

The latest short interest is 1.30 million, so 1.72% of the outstanding shares have been sold short.

Short Interest	1.30M
Short Previous Month	1.03M
Short % of Shares Out	1.72%
Short % of Float	1.90%
Short Ratio (days to cover)	1.95

Income Statement

In the last 12 months, IGC Pharma had revenue of $1.06 million and -$13.30 million in losses. Loss per share was -$0.21.

Revenue	1.06M
Gross Profit	641,000
Operating Income	-10.05M
Pretax Income	-13.30M
Net Income	-13.30M
EBITDA	-9.41M
EBIT	-10.05M
Loss Per Share	-$0.21

Balance Sheet

The company has $1.82 million in cash and $338,000 in debt, giving a net cash position of $1.49 million or $0.02 per share.

Cash & Cash Equivalents	1.82M
Total Debt	338,000
Net Cash	1.49M
Net Cash Per Share	$0.02
Equity (Book Value)	7.88M
Book Value Per Share	0.10
Working Capital	1.92M

Cash Flow

In the last 12 months, operating cash flow was -$5.48 million and capital expenditures -$156,000, giving a free cash flow of -$5.64 million.

Operating Cash Flow	-5.48M
Capital Expenditures	-156,000
Free Cash Flow	-5.64M
FCF Per Share	-$0.07

Margins

Gross Margin	60.36%
Operating Margin	-946.23%
Pretax Margin	-1,252.64%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-530.89%

Dividends & Yields

IGC Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.46%
Shareholder Yield	-20.46%
Earnings Yield	-46.43%
FCF Yield	-19.68%

Analyst Forecast

The average price target for IGC Pharma is $3.63, which is 855.26% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$3.63
Price Target Difference	855.26%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on April 19, 2013. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Apr 19, 2013
Split Type	Reverse
Split Ratio	0.1:1

Scores

IGC Pharma has an Altman Z-Score of -12.98 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-12.98
Piotroski F-Score	4